Drugs Should Get Longer Patents In Exchange For More Safety Data – Wood
Executive Summary
Offering extended exclusivity, in advance, for drugs that address an unmet medical need could bring a necessary boost to research and development efforts, Vanderbilt University's Alastair Wood said
You may also be interested in...
Waxman To Seek Consensus On FOBs, Incentives For Early Patent Resolution
Efforts will be made "over the next few months" to bring House Energy and Commerce Committee members to a consensus on a follow-on biologics bill, according to committee staffer Ann Witt
Waxman To Seek Consensus On FOBs, Incentives For Early Patent Resolution
Efforts will be made "over the next few months" to bring House Energy and Commerce Committee members to a consensus on a follow-on biologics bill, according to committee staffer Ann Witt
Phase III Could Be Replaced With “Targeted Approval” – Manhattan Institute
The need for Phase III clinical trials would be reduced if sponsors use validated biomarkers in Phase II studies under a Manhattan Institute proposal